Salubris disclosed that as of September 30, 2026, the company had repurchased 8.32 million shares, accounting for 0.75% of total share capital, with repurchase transaction prices ranging from 29.28 yuan to 40.8 yuan per share, and total repurchase funds paid amounting to 266 million yuan. In the first half of 2026, Salubris achieved revenue of 2.479 billion yuan and net profit attributable to the parent of 387 million yuan.
Shenzhen Salubris Pharmaceuticals Co LtdSalubris repurchased 8.32 million shares for 266 million yuan, a buyback that returns capital to shareholders.
